Compare GMAB & FN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMAB | FN |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | Denmark | Cayman Islands |
| Employees | 3029 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 23.7B |
| IPO Year | N/A | 2007 |
| Metric | GMAB | FN |
|---|---|---|
| Price | $26.56 | $680.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $39.56 | ★ $513.43 |
| AVG Volume (30 Days) | ★ 1.5M | 604.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.21 |
| EPS | N/A | ★ 5.77 |
| Revenue | N/A | ★ $3,419,327,000.00 |
| Revenue This Year | $17.85 | $36.87 |
| Revenue Next Year | $16.04 | $17.91 |
| P/E Ratio | ★ $1.90 | $118.69 |
| Revenue Growth | N/A | ★ 18.60 |
| 52 Week Low | $18.89 | $193.54 |
| 52 Week High | $35.43 | $734.79 |
| Indicator | GMAB | FN |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 57.50 |
| Support Level | $24.95 | $429.50 |
| Resistance Level | $29.64 | N/A |
| Average True Range (ATR) | 0.54 | 37.41 |
| MACD | -0.18 | -5.91 |
| Stochastic Oscillator | 21.29 | 49.87 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.